Volume | 73,018 |
|
|||||
News | - | ||||||
Day High | 39.73 | Low High |
|||||
Day Low | 35.1636 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Corbus Pharmaceuticals Holdings Inc | CRBP | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
35.42 | 35.1636 | 39.73 | 35.57 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,674 | 73,018 | $ 37.86 | $ 2,764,701 | - | 3.0334 - 49.8699 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
12:59:31 | 15 | $ 38.66 | USD |
Corbus Pharmaceuticals Holdings Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
409.23M | 10.49M | - | 0 | -42.35M | -4.04 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Corbus Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CRBP Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 38.70 | 39.73 | 33.2398 | 36.34 | 252,852 | -0.03 | -0.08% |
1 Month | 28.25 | 49.8699 | 26.8188 | 39.61 | 402,784 | 10.42 | 36.88% |
3 Months | 6.05 | 49.8699 | 5.6654 | 29.24 | 991,205 | 32.62 | 539.17% |
6 Months | 6.35 | 49.8699 | 3.0334 | 28.80 | 468,523 | 32.32 | 508.98% |
1 Year | 6.69 | 49.8699 | 3.0334 | 26.87 | 259,961 | 31.98 | 478.03% |
3 Years | 57.834 | 68.70 | 2.11 | 21.86 | 1,382,468 | -19.16 | -33.14% |
5 Years | 208.50 | 322.50 | 2.11 | 66.23 | 2,212,690 | -169.83 | -81.45% |
Corbus Pharmaceuticals Description
Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune system. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. |